Purified fragments of genetic material, injected into tissue needing repair, calm inflammation and encourage new blood vessels. Strongest support: closing stubborn foot ulcers in people with diabetes, and brief knee pain relief. Tendon pain and scar prevention rest on thinner evidence; the large cosmetic skin market has the weakest. Harms appear modest and local; nothing followed beyond about six months. (Full Review)

Protocol

Wound and ulcer protocol

One ampoule intramuscularly

5 days a week, plus one ampoule around the ulcer margin twice weekly, for 8 weeks alongside standard wound care

Intra-articular knee protocol

One 5.625 mg/3 mL ampoule

Injected into the joint weekly for 3 weeks; often combined with hyaluronic acid in the same course

Peritendinous protocol

One 5.625 mg/3 mL ampoule

Around the affected tendon weekly for 3–4 weeks, frequently paired with shockwave therapy or a strengthening programme

Time to effect

Wound closure

4–8 weeks

Differences emerge over the 8-week course given alongside standard wound care

Joint pain relief

1–4 weeks

Fades over 2–4 months after a course

Visible skin change

4–8 weeks

Peaks around 3 months after two sessions; gains decline over 4–9 months

Benefits

High: Healing of chronic diabetic foot ulcers; short-term pain relief in knee osteoarthritis

Medium: Reduction of tendon and ligament pain; prevention of hypertrophic surgical scarring

Low: Improvement in skin texture, elasticity and fine wrinkles; improvement in atrophic acne scarring

Speculative: Preservation of SIRT1 and delay of cellular senescence; bone and cartilage regeneration

Contraindications

Known hypersensitivity to fish, seafood, or any salmonid-derived product

Active infection at or adjacent to the intended injection site

Active or recently treated malignancy (within 5 years)

Pregnancy and lactation, at any stage

Platelet count below 50 × 10⁹/L, or INR above 3.0

Uncontrolled diabetes with glycated haemoglobin above 9.0%

Autoimmune connective-tissue disease in active flare

Key Interactions

Methylxanthines (caffeine, theophylline, aminophylline)

Adenosine-potentiating drugs (dipyridamole, regadenoson)

Anticoagulants and antiplatelet drugs (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin)

Systemic corticosteroids (prednisone, dexamethasone)

Immunosuppressants (ciclosporin, tacrolimus, methotrexate, biologics)

Over-the-counter analgesics (ibuprofen, naproxen, high-dose aspirin)

Supplements with antiplatelet activity (fish oil, vitamin E, ginkgo, garlic extract, high-dose curcumin)

Supplements affecting adenosine tone (caffeine-containing pre-workouts, theacrine, high-dose niacin)

Other injectable interventions (hyaluronic acid, platelet-rich plasma, corticosteroid injection, energy-based devices)

Risk & Side Effects

High: Transient injection-site pain, swelling and erythema

Medium: Palpable papules and nodules after intradermal injection; absence of long-term safety data

Low: Hypersensitivity and allergic reactions; injection-related infection and bruising

Speculative: Tumour promotion through adenosine A2A signalling; unintended systemic effects of repeated intramuscular dosing

Monitoring

Marker	Target	Why
Glycated haemoglobin	4.8–5.4%	Predicts repair capacity
High-sensitivity C-reactive protein	Below 1.0 mg/L	Baseline inflammatory load
Platelet count	150–400 × 10⁹/L	Bruising and haematoma risk at injection points
International normalised ratio	0.9–1.1 if not anticoagulated	Clotting time; determines whether periorbital injection is safe
Estimated glomerular filtration rate	Above 90 mL/min/1.73 m²	General clearance capacity and a marker of microvascular health
Serum albumin	4.2–5.0 g/dL	Protein availability for collagen synthesis
Serum uric acid	3.5–5.5 mg/dL	Reflects purine load, which PDRN adds to
Transcutaneous oxygen tension	Above 40 mmHg	Identifies the perfusion-limited tissue most likely to respond
Fish-specific immunoglobulin E	Record present or absent	Screens for the hypersensitivity risk created by the salmonid source

Cadence: Reassessment at 4 weeks after the first session, at the end of the course, then at 3 and 6 months; annual review beyond six months

Qualitative Assessment

Pain on a 0–10 scale for the specific joint or tendon treated, recorded at the same time of day
Standardised photographs under fixed lighting for skin indications, reviewed at 4 weeks, 3 months and 6 months
Subjective skin firmness, hydration and texture, rated weekly
Range of motion and functional capacity for the treated structure
Duration and severity of post-injection redness, as an early signal of hypersensitivity
Energy levels and sleep quality, to separate genuine treatment effect from general wellbeing drift

PDRN for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment